1232759

Vanda Pharmaceuticals Inc — FEI 3006750765

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
March 12, 2024
Fiscal Year
2024
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Washington, DC (United States)

Additional Details

Sponsor, Contract Research Organization

Citations

IDCFRDescription
738821 CFR 50.25(a)(2)Reasonably foreseeable risks or discomforts
755721 CFR 312.56(b)Notification of FDA of termination of investigator